HC Wainwright Reiterates "Buy" Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $16.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 421.17% from the stock's current price.

Separately, StockNews.com downgraded AC Immune from a "buy" rating to a "hold" rating in a research note on Tuesday, October 1st.

AC Immune Stock Down 5.2 %

Shares of NASDAQ ACIU traded down $0.17 during midday trading on Wednesday, reaching $3.07. 60,618 shares of the company were exchanged, compared to its average volume of 348,471. AC Immune has a one year low of $2.25 and a one year high of $5.14. The stock has a market cap of $303.75 million, a P/E ratio of -4.50 and a beta of 1.28. The stock's 50-day moving average price is $3.27 and its 200-day moving average price is $3.45.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($0.67). The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $91.60 million. On average, equities research analysts anticipate that AC Immune will post -0.89 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ACIU. Lazard Asset Management LLC purchased a new position in AC Immune during the 1st quarter worth approximately $30,000. BNP Paribas Financial Markets boosted its holdings in AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company's stock valued at $33,000 after purchasing an additional 8,423 shares during the period. Silverberg Bernstein Capital Management LLC acquired a new stake in AC Immune in the second quarter valued at approximately $40,000. Vanguard Capital Wealth Advisors purchased a new stake in AC Immune during the 2nd quarter worth about $56,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock valued at $72,000 after acquiring an additional 7,400 shares during the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.